PT - JOURNAL ARTICLE AU - P Grandjean AU - C.A.G. Timmermann AU - M. Kruse AU - F. Nielsen AU - P. Just Vinholt AU - L. Boding AU - C. Heilmann AU - K. Mølbak TI - Severity of COVID-19 at elevated exposure to perfluorinated alkylates AID - 10.1101/2020.10.22.20217562 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.22.20217562 4099 - http://medrxiv.org/content/early/2020/10/26/2020.10.22.20217562.short 4100 - http://medrxiv.org/content/early/2020/10/26/2020.10.22.20217562.full AB - Background The course of coronavirus disease 2019 (COVID-19) seems to be aggravated by air pollution, and some industrial chemicals, such as the perfluorinated alkylate substances (PFASs), are immunotoxic and may contribute as well.Methods From Danish biobanks, we obtained plasma samples from 323 subjects aged 30-70 years with known SARS-CoV-2 infection. The PFAS concentrations measured at the background exposures included five PFASs known to be immunotoxic. Register data was obtained to classify disease status, other health information, and demographic variables. We used ordinal and ordered logistic regression analyses to determine associations between PFAS concentrations and disease outcome.Results Plasma-PFAS concentrations were higher in males, in subjects with Western European background, and tended to increase with age, but were not associated with the presence of chronic disease. Of the study population, 108 (33%) had not been hospitalized, and of those hospitalized, 53 (16%) had been in intensive care or were deceased. Among the five PFASs considered, perfluorobutanoic acid (PFBA) showed an odds ratio (OR) of 2.19 (95% confidence interval, CI, 1.39-3.46) for increasing severities of the disease, although the OR decreased to 1.77 (95% CI, 1.09, 2.87) after adjustment for age, sex, sampling site and interval between blood sampling and diagnosis.Conclusions Measures of individual exposures to immunotoxic PFASs included PFBA that accumulates in the lungs. Elevated plasma-PFBA concentrations were associated with an increased risk of more severe course of CIVID-19. Given the low background exposure levels in this study, the role of PFAS exposure in COVID-19 needs to be ascertained in populations with elevated exposures.Competing Interest StatementApart from PG having served as health expert in lawsuits on environmental contamination, the authors have no competing interests to declare, financial or otherwise.Funding StatementThis study was supported by a grant from the Novo Nordisk Foundation (NNF20SA0062871) to cover the efforts at Statens Serum Institut. Dr. Grandjean is supported by the National Institute for Environmental Health Sciences (ES027706). All funding sources are public, and no private funding was involved. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the Danish Regional Committee on Health Research Ethics (S-20200064), the Danish Health Data Authority (FSEID-00005000), and regional and institutional authorities.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData contain personal information on study participants and were uploaded to the secure server at the Danish Health Data Authority, where they are available pending necessary approvals. Aggregated data that involve at least five subjects are available from the authors.